Rather than framing long COVID as a simple state of persistent systemic inflammation, this new study points toward a model of chronically dysregulated immunity in which NK-cell dysfunction may occupy a central mechanistic role🧵
This paper says something important. In at least a subset of patients, long COVID may represent a state of impaired, inefficient, and partly exhausted immune surveillance, with NK cells at its center.
The authors support this with three layers of evidence. SARS-CoV-2 antibodies persist in the blood, while key cytokines fall, NK/NKT cells are reduced in number, and the NK cells that remain carry transcriptional signatures of functional remodeling and suppression.
The first point is that the study shifts the picture of long COVID away from the simple idea of persistent systemic inflammation toward a model of chronically dysregulated immunity.
If this were pure hyperinflammation, we would expect persistently elevated pro-inflammatory mediators. Instead, IFN-γ, TNF-α, IL-6, and IL-10 all decline - meaning not only inflammatory drivers but also regulatory brakes are reduced.
The authors themselves describe it as a dampened, hyporesponsive state resembling a prolonged refractory phase or immune exhaustion.
The second point is that NK cells are not just one more marker among many here. They are a candidate nodal mechanism. NK cells are part of the early antiviral defense, but they are also a regulatory bridge between innate and adaptive immunity.
If their numbers fall and they produce less TNF-α, that may mean the host is less able to recognize and clear residual pathological signals - whether those are persistent antigens, tissue damage, or self-sustaining immune activation.
The third point is that the paper suggests long COVID is not simply more of the same after infection. Some changes are shared with ordinary convalescence, but others point more specifically to a failure to return to baseline.
This includes, above all, poorer coordination between innate and adaptive immunity and incomplete resolution of activation.
The fourth point is the link to neurological and sensory symptoms, which is particularly interesting. In NK cells, the authors identify suppression of pathways related to smell, taste, neurotransmitter receptors, and GABA signaling.
it suggests that the gene programs of these cells reflect a a broader neuroimmune reorganization of the organism.
So the immune system is no longer just a defensive apparatus. It becomes an imprint of a systemic disorder that may clinically manifest as fatigue, anosmia, and brain fog. This is a bold but biologically interesting interpretation.
The fifth point is that elevated antibodies together with reduced cellular functionality create a striking contrast. The humoral response persists, while cellular immune surveillance appears dampened.
The immune system remains chronically exposed to some stimulus, but instead of eliminating it effectively, it shifts into a maladaptive mode. That is compatible with antigen persistence, although the study does not prove antigen persistence on its own.
NK cells emerge in this study as a likely important node - not necessarily the only cause, but very plausibly one of the main mechanistic links.
Practically, this implies three things. First, biomarkers of long COVID may not be limited to high inflammation, but may also include pathologically low or poorly coordinated immune responses.
Second, therapies aimed only at suppressing inflammation may not be appropriate for all patients. In some, the problem may theoretically be immune inefficiency rather than excess immune activity.
Third, it makes sense to look for immunological subtypes of long COVID rather than treating all patients as one biological group.
Sum:
This study interprets long COVID not as simple persistent inflammation, but as a disorder of failed immune reequilibration in which NK cells are faltering both as effectors and as regulators.
Ray at al., Dysregulated NK-cell gene expression defines the enduring symptoms of long COVID-19. frontiersin.org/journals/immun…
Insides:
One consistent signal in this long COVID cohort - persistent SARS-CoV-2 antibodies.
IgG against Spike S1, RBD and N remained elevated even months after infection - in some cases up to 500 days.
This suggests the immune system may still be sensing persistent antigen exposure long after acute disease.
Long COVID patients in this study did not show a classic hyperinflammatory profile.
Key cytokines - IFN-γ, TNF-α, IL-6 and IL-10 - were significantly reduced.
This pattern is more consistent with immune hyporesponsiveness or exhaustion rather than persistent inflammation.
Flow cytometry revealed reduced CD56+CD16 NK cells and CD56+ CD3NKT cells.
NK cells are essential for antiviral surveillance.
Their decline - together with altered expression of genes such as CXCR4, PDCD4 and SLC7A5 - suggests functional remodeling of the NK compartment.
Single-cell RNA-seq identified transcriptional changes in NK cells linked to neurosensory pathways.
Genes related to smell and neuronal signaling - including OR1L8, OR52H1, OMP and SLC6A3 - were downregulated.
This points toward a potential neuro-immune axis underlying anosmia and cognitive symptoms in long COVID.
• • •
Missing some Tweet in this thread? You can try to
force a refresh
A new long COVID study found that standard autoimmune blood tests often looked normal. But when researchers tested patients blood directly against heart and blood vessel tissue, they found persistent immune reactivity - especially involving vascular tissue.🧵
The study found tissue-specific autoreactivity in many long COVID patients - especially against vascular tissue - while standard ANA screening often looked normal.
They found tissue-specific autoreactivity in 83% of long COVID patients vs 53% of pre-pandemic controls.
The clearest statistically significant difference was against vascular tissue.
34% in long COVID vs 8% in controls.
SARS-CoV-2/spike RBD may act as a potential modifier of glioma progression in biologically susceptible cells. An interesting mechanistic study that raises a warning signal.🧵
Methods first.
This study combines single-cell RNA, bulk RNA-seq, spatial transcriptomics, survival analysis, pathway/enrichment analysis, and in vitro experiments on primary glioblastoma cells.
The authors looked at genes and proteins linked to SARS-CoV-2 cell entry
ACE2, BSG/CD147, NRP1, TMPRSS2, FURIN, FCGR1A, HSPG2.
These factors were mapped across healthy brain cells, COVID-19 brain samples, glioma cells, and glioma tissue.
COVID-19 and the heart. A new narrative synthesis of 71 studies suggests that long-term cardiovascular effects are not limited to people who were hospitalised.
The risk is clearly highest after severe acute disease - but measurable abnormalities have also been reported after mild infections🧵
This is not a meta-analysis.
The authors did not calculate one pooled prevalence estimate because the studies were too uneven. Different LC definitions, different follow-up, tests, different populations, and often poor separation between hospitalised and non hospitalised groups.
Even with that messiness, the same warning signal keeps appearing.
COVID-19 can be followed by persistent cardiovascular problems - palpitations, chest pain, shortness of breath, fatigue, arrhythmias, dysautonomia, impaired heart function, and in higher-risk groups, major adverse cardiovascular events.
A new study in Frontiers in Cardiovascular Medicine looked at a very important question.
Can a history of COVID-19 be linked to impaired coronary blood flow, even when the main coronary arteries look normal?🧵
The authors included 190 patients with unstable angina and normal coronary arteries.
Half of them had a confirmed history of COVID-19.
The other half did not.
The key difference between the two groups was previous COVID infection.
The result was striking.
Patients with prior COVID-19 had a much higher rate of coronary slow flow.
COVID+ group 18.9%
COVID− group 5.3%
That is more than a threefold difference.
Why do some people develop life-threatening viral disease, while others clear the same virus with only mild symptoms?
One answer is becoming clearer.
In some people, the first line of antiviral defense is already weakened before the virus arrives🧵
That first line is type I interferon.
Type I - especially IFN-α and IFN-ω - act like an early alarm system. When a virus enters the body, they help cells switch into an antiviral state before the infection spreads too far.
A landmark study from the Casanova lab found that some patients with life-threatening COVID-19 had autoantibodies that neutralized type I interferons.
In that cohort, these neutralizing autoantibodies were found in about 10% of critical COVID-19 cases.
A new JAMA Neurology meta analysis on pure autonomic failure (PAF) is highly relevant to the broader discussion around POTS, long COVID dysautonomia, and early neurodegeneration.
Not because PAF is the same as POTS.
It is not. But…🧵@DavidJoffe64
It is important because it shows what can be learned when an autonomic syndrome is carefully defined and followed over time.
PAF is a form of autonomic failure, usually marked by neurogenic orthostatic hypotension.
In simple terms. When a person stands up, blood pressure drops, and the autonomic nervous system fails to compensate properly.
That is very different from simply feeling dizzy on standing.